Liposomal Delivery Enhances the Effects of a Collagen Tripeptide-Containing Formulation on Dermal Structure and Optical Skin Parameters: A Randomized, Double-Blind, Placebo-Controlled Trial

What Was Tested

This randomized controlled trial paper looks at Tripeptide-29 (Collagen Tripeptide).

This study aimed to determine whether liposomal delivery enhances the effects of a collagen tripeptide-containing formulation on dermal structural and biomechanical parameters, as well as appearance-related skin properties, compared with a nonliposomal formulation and placebo.

Objective assessments of dermal collagen density, skin hydration, elasticity, wrinkle area, skin luminance, and tone evenness were performed at baseline and Weeks 2, 4, and 8 using standardized instrumental measurements.

Who Took Part

The study group was 75 adults.

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

The adults were allocated by chance, so the Tripeptide-29 (Collagen Tripeptide) group and the comparison group should start out alike.

Neither the adults nor the staff measuring them knew who was on Tripeptide-29 (Collagen Tripeptide), so expectations could not easily colour the readings.

Some adults received a placebo instead of Tripeptide-29 (Collagen Tripeptide), giving a reference point.

A time span of 8 weeks appears in the methods.

What Was Measured

Topics PubMed links to this paper include Liposomes, Skin Aging, Collagen, Elasticity, Oligopeptides, Skin and Administration, Cutaneous.

Author keywords: collagen tripeptides, dermal collagen, liposomal delivery, skin elasticity, skin luminance and skin physiology.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Tripeptide-29 (Collagen Tripeptide) in 75 adults over 8 weeks.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2026 (Journal of cosmetic dermatology), a journal based in England.

More context: the Tripeptide-29 (Collagen Tripeptide) compound page, all human trials.